Cargando…

PHASE 3 STUDY OF SAFETY AND IMMUNOGENICITY OF GBP510 VACCINE ADJUVANTED WITH AS03 IN ADULTS

INTRO: GBP510 contains the self-assembling recombinant nanoparticle displaying SARS‐CoV-2 Spike protein receptor binding domain and is adjuvanted with AS03. We report interim Phase 3 study (NCT05007951) results up to 4 weeks post-dose 2 (Data-cut: March-18-2022), where immunogenicity to the D614G an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, J.Y., Choi, W.S., Cheong, H.J., Kim, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186949/ http://dx.doi.org/10.1016/j.ijid.2023.04.344

Ejemplares similares

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
por: Song, Joon Young, et al.
Publicado: (2023)

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial
por: Song, Joon Young, et al.
Publicado: (2022)

Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
por: Jacob-Dolan, Catherine, et al.
Publicado: (2023)

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
por: Charland, Nathalie, et al.
Publicado: (2022)

Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03(B) adjuvant: Results of a randomized phase I trial
por: Levy, Jack, et al.
Publicado: (2015)

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
por: Carmona Martinez, Alfonso, et al.
Publicado: (2014)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
por: Madan, Anuradha, et al.
Publicado: (2016)

Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study
por: Lin, Leyi, et al.
Publicado: (2020)

Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine
por: De Serres, Gaston, et al.
Publicado: (2012)

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2016)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

Toward Soluble 5,10-Diheterotruxenes: Synthesis and Reactivity of 5,10-Dioxatruxenes, 5,10-Dithiatruxenes, and 5,10-Diazatruxenes
por: Górski, Krzysztof, et al.
Publicado: (2020)

Murine Gbp1 and Gbp2 are ubiquitinated independent of Toxoplasma gondii infection
por: Encheva, Vesela, et al.
Publicado: (2018)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
por: de Bruyn, Guy, et al.
Publicado: (2023)

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial
por: Schuind, Anne, et al.
Publicado: (2015)

A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin(®)) in Healthy Chinese Males
por: Wu, Jing, et al.
Publicado: (2023)

Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England
por: Yung, Chee-Fu, et al.
Publicado: (2013)

Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study
por: Kim, Joon Hyung, et al.
Publicado: (2021)

Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination
por: Díez-Domingo, Javier, et al.
Publicado: (2015)

Immunogenicity of Calvenza-03 EIV/EHV(®) Vaccine in Horses: Comparative In Vivo Study
por: Pavulraj, Selvaraj, et al.
Publicado: (2021)

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial()
por: Yang, William H., et al.
Publicado: (2013)

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
por: Li, Rongcheng, et al.
Publicado: (2008)

Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.
por: Kompier, Ronald, et al.
Publicado: (2022)

Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines
por: Shrestha, Ashish C., et al.
Publicado: (2019)

Whole exome capture in solution with 3 Gbp of data
por: Bainbridge, Matthew N, et al.
Publicado: (2010)

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
por: Sridhar, Saranya, et al.
Publicado: (2022)

LPS-aggregating proteins GBP1 and GBP2 are each sufficient to enhance caspase-4 activation both in cellulo and in vitro
por: Dickinson, Mary S., et al.
Publicado: (2023)

Human GBP1 Is Involved in the Repair of Damaged Phagosomes/Endolysosomes
por: Buijze, Hellen, et al.
Publicado: (2023)

Safety and immunogenicity of AS03(B) adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
por: Waddington, Claire S, et al.
Publicado: (2010)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
por: Oostvogels, Lidia
Publicado: (2017)

Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture
por: Vorovitch, Mikhail F., et al.
Publicado: (2020)

Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial
por: Danko, Janine R., et al.
Publicado: (2018)

Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants
por: Reinke, Sören, et al.
Publicado: (2020)

Various Adjuvants Effect on Immunogenicity of Puumala Virus Vaccine
por: Kurashova, Svetlana S., et al.
Publicado: (2020)

Evaluation of the Olympus AU-510 analyser
por: Farré, Carmen, et al.
Publicado: (1991)

Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults
por: Choi, Won Suk, et al.
Publicado: (2016)

Observatory wins GBP 10.6m contract
por: Dalton, A W
Publicado: (2003)

Space explorers get GBP35m boost
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_fq9gjkvs58v62net418jla19u2